Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence
Article first published online: 19 OCT 2009
© 2009 The Authors. Journal compilation © 2009 Society for the Study of Addiction
Volume 105, Issue 1, pages 146–154, January 2010
How to Cite
Longo, M., Wickes, W., Smout, M., Harrison, S., Cahill, S. and White, J. M. (2010), Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction, 105: 146–154. doi: 10.1111/j.1360-0443.2009.02717.x
- Issue published online: 14 DEC 2009
- Article first published online: 19 OCT 2009
- Submitted 25 September 2008; initial review completed 8 December 2008; final version accepted 19 June 2009
- randomized controlled trial;
Aim To investigate the safety and efficacy of once-daily supervised oral administration of sustained-release dexamphetamine in people dependent on methamphetamine.
Design Randomized, double-blind, placebo-controlled trial.
Participants Forty-nine methamphetamine-dependent drug users from Drug and Alcohol Services South Australia (DASSA) clinics.
Intervention Participants were assigned randomly to receive up to 110 mg/day sustained-release dexamphetamine (n = 23) or placebo (n = 26) for a maximum of 12 weeks, with gradual reduction of the study medication over an additional 4 weeks. Medication was taken daily under pharmacist supervision.
Measurements Primary outcome measures included treatment retention, measures of methamphetamine consumption (self-report and hair analysis), degree of methamphetamine dependence and severity of methamphetamine withdrawal. Hair samples were analysed for methamphetamine using liquid chromatography-mass spectrometry.
Findings Treatment retention was significantly different between groups, with those who received dexamphetamine remaining in treatment for an average of 86.3 days compared with 48.6 days for those receiving placebo (P = 0.014). There were significant reductions in self-reported methamphetamine use between baseline and follow-up within each group (P < 0.0001), with a trend to a greater reduction among the dexamphetamine group (P = 0.086). Based on hair analysis, there was a significant decrease in methamphetamine concentration for both groups (P < 0.0001). At follow-up, degree of methamphetamine dependence was significantly lower in the dexamphetamine group (P = 0.042). Dexamphetamine maintenance was not associated with serious adverse events.
Conclusions The results of this preliminary study have demonstrated that a maintenance pharmacotherapy programme of daily sustained-release amphetamine dispensing under pharmacist supervision is both feasible and safe. The increased retention in the dexamphetamine group, together with the general decreases in methamphetamine use, degree of dependence and withdrawal symptom severity, provide preliminary evidence that this may be an efficacious treatment option for methamphetamine dependence.